Results 1 to 10 of about 387,299 (303)

Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol

Nature Communications, 2023
The interplay between western diet and gut microbiota drives the development of non-alcoholic fatty liver disease and its progression to non-alcoholic steatohepatitis.
Shi-You Chen, Aaron C Ericsson, Ming Yang   +2 more
exaly   +3 more sources

Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis

Journal of Hepatology, 2022
BACKGROUND & AIMS Non-alcoholic steatohepatitis (NASH) is associated with the dysregulation of lipid metabolism and hepatic inflammation. The mechanism underlying NASH is unclear.
Ling Lu, Haoming Zhou
exaly   +2 more sources

Recurrent and de novo non-alcoholic steatohepatitis following orthotopic liver transplantation [PDF]

Arquivos de Gastroenterologia, 2001
Background — Non-alcoholic steatohepatitis was coined in 1980 to describe pathological and clinical features of non-alcoholic disease associated with pathological features, commonly seen in alcoholic-liver disease itself.
Raquel F. Liermann GARCIA, Eugenia MORALES, Christian Evangelista GARCIA, Sushma SAKSENA, Stefan G. HÜBSCHER, Elwin ELIAS   +5 more
doaj   +1 more source

Immune cell-mediated features of non-alcoholic steatohepatitis

Nature reviews. Immunology, 2021
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations, starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis (NASH), cirrhosis or even hepatocellular carcinoma. NAFLD is a major health
T. Huby, E. Gautier
semanticscholar   +1 more source

MACROPHAGE-DERIVED OSTEOPONTIN (SPP1) PROTECTS FROM NON-ALCOHOLIC STEATOHEPATITIS

Gastroenterology, 2023
Background & Aims: Non-alcoholic steatohepatitis (NASH) is characterized by steatosis, lobular inflammation, hepatocyte ballooning degeneration and fibrosis, all of which increase the risk of progression to end-stage liver disease. Osteopontin (OPN, SPP1)
Hui-Jing Han, Xiaodong Ge, Sai Santosh Babu Komakula, R. Désert, Sukanta Das, Zhuo-Lun Song, Wei Chen, D. Athavale, Harriet Gaskell, Daniel Lantvit, G. Guzman, N. Nieto   +11 more
semanticscholar   +1 more source

Metabolic preconditions for the formation and progression of steatohepatitis of alcoholic, mixed, non-alcoholic aetiology and their comorbidity with obesity and anaemic conditions

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Background. The urgency of the problem of comorbidity of alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH) with anaemic conditions and the need for their differentiated correction is determined by the significant frequency of these
T. Antofiichuk, O. Khukhlina, M. Antofiichuk, N. Kaspruk   +3 more
doaj   +1 more source

Treatments for NAFLD [PDF]

Farmacja Polska, 2021
Non-alcoholic fatty liver disease (NAFLD) is categorised into simple steatosis, termed nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH).
Katarzyna Juszczyńska
doaj   +1 more source

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis

Nature Medicine, 2023
There are no approved diagnostic biomarkers for at-risk non-alcoholic steatohepatitis (NASH), defined by the presence of NASH, high histological activity and fibrosis stage ≥2, which is associated with higher incidence of liver-related events and ...
A. Sanyal, Sudha S. Shankar, Katherine P. Yates, J. Bolognese, Erika Daly, Clayton A. Dehn, B. Neuschwander‐Tetri, Kris V. Kowdley, R. Vuppalanchi, C. Behling, J. Tonascia, Anthony Samir, C. Sirlin, Sarah P Sherlock, Kathryn J. Fowler, Helen Heymann, Tania N. Kamphaus, R. Loomba, Roberto A Calle   +18 more
semanticscholar   +1 more source

Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children

Frontiers in Microbiology, 2021
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in western countries both in children and adults. Metabolic dysregulation associated with gut microbial dysbiosis may influence disease progression from hepatic ...
Kattayoun Kordy, Kattayoun Kordy, Fan Li, David J. Lee, Jason M. Kinchen, Michael H. Jew, Maria Eduarda La Rocque, Sara Zabih, Monica Saavedra, Cora Woodward, Nicole J. Cunningham, Nicole H. Tobin, Grace M. Aldrovandi   +12 more
doaj   +1 more source

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

The Lancet Gastroenterology and Hepatology, 2020
Summary Background The burden of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and a major priority is to identify patients with non-alcoholic steatohepatitis (NASH) who are at greater risk of progression to cirrhosis, and who will be
P. Newsome, M. Sasso, J. Deeks, A. Paredes, J. Boursier, W. Chan, Y. Yılmaz, S. Czernichow, M. Zheng, V. Wong, M. Allison, E. Tsochatzis, Q. Anstee, D. Sheridan, P. Eddowes, I. Guha, J. Cobbold, V. Paradis, P. Bedossa, V. Miette, C. Fournier-Poizat, L. Sandrin, S. Harrison   +22 more
semanticscholar   +1 more source